A Phase I, Randomised, Open-Label, Single and Multiple Ascending Dose (Twice-Daily), Incomplete Block, Cross-Over Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide Administered by Inhalation in Healthy Chinese Subjects
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Aclidinium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 12 Oct 2017 Planned End Date changed from 23 Oct 2017 to 24 Jan 2018.
- 12 Oct 2017 Planned primary completion date changed from 23 Oct 2017 to 24 Jan 2018.
- 12 Oct 2017 Planned initiation date changed from 20 Sep 2017 to 22 Dec 2017.